Carl Zeiss Meditec AG
Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013 - Seite 2
Outlook - well equipped for further growth
With consistent expansion of our solutions business, based on a broad product range and a balanced regional distribution of business, the Company is sticking firmly to its goals to increase the share of case-number-dependent products and services to 25% by 2015 and to achieve a total EBIT margin of 15%. Steady growth is expected for the current financial year. "We anticipate revenue of between € 880 and 910 million," says Ludwin Monz.
Revenue by strategic business unit
Figures in € '000 | 6 Months 2011/2012 | 6 Months 2012/2013 | Change from previous year |
Ophthalmic Systems | 184,781 | 175,766 | -4.9% |
Surgical Ophthalmology | 51,942 | 60,459 | 16.4% |
Microsurgery | 195,075 | 206,732 | 6.0% |
Revenue by region
Figures in € '000 | 6 Months 2011/2012 | 6 Months 2012/2013 | Change from previous year |
EMEA | 149,423 | 152,625 | 2.1% |
Americas | 144,083 | 143,875 | -0.1% |
Asia / Pacific region | 138,292 | 146,457 | 5.9% |
Press contacts:
Jann Gerrit Ohlendorf, Corporate Communications, Carl Zeiss Meditec AG
Phone+49 3641 220-331, E-Mail: press.meditec@zeiss.com
Contact for investors:
Henriette Meyer, Investor Relations, Carl Zeiss Meditec AG
Phone +49 3641 220-106, E-Mail: investors.meditec@zeiss.com
www.meditec.zeiss.com/press
Lesen Sie auch
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The company supplies innovative
technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of
eye diseases, including implants and consumable materials. The company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss
Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2011/2012 (ended 30 September) the Group's more than 2,400 employees
generated revenue of almost € 862 million. The head office of Carl Zeiss Meditec is in Jena, Germany.